Patents Examined by Bruce R. Campell
  • Patent number: RE48751
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: September 28, 2021
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Patent number: RE48801
    Abstract: This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: November 2, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D, Universiteit Gent
    Inventors: Jean-Christophe Marine, Eleonora Leucci, Joke Vandesompele, Pieter Mestdagh
  • Patent number: RE48856
    Abstract: The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 21, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Jean-Christophe Marine, Laura Standaert
  • Patent number: RE48864
    Abstract: The present application describes an optimized medium for growth of mammalian cells as well as polypeptide production. The cell culture medium is characterized by a Sow ratio of sodium to potassium ions, it further relates to the method of producing polypeptides using such cell culture media. Sn another aspect, the method of polypeptide production can also comprise a temperature shift and/or a pH-shift to further optimize growth and product yield.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: December 28, 2021
    Assignee: Novartis AG
    Inventors: Christian Leist, Petra Meissner, Jörg Schmidt
  • Patent number: RE48887
    Abstract: This invention provides compositions for use in distributing active agents for treating a malignant tumor in a subject. The compositions contain RNAi molecules targeted to a human GST-?, along with RNAi molecules targeted to a human p21, and a pharmaceutically acceptable carrier. The carrier can include nanoparticles composed of an ionizable lipid, a structural lipid, one or more stabilizer lipids, and a lipid for reducing immunogenicity of the nanoparticles. This invention further provides methods for preventing or treating a malignant tumor by administering a therapeutically effective amount of an RNAi composition.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: January 11, 2022
    Assignee: NITTO DENKO CORPORATION
    Inventors: Yoshiro Niitsu, Kenjirou Minomi, Bharat Majeti, Li Wang, Jihua Liu, Roger Adami, Wenbin Ying
  • Patent number: RE49026
    Abstract: The present invention relates to novel linear and cyclic polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides (linear or cyclic), and use of same in inhibiting cell functions including production of IL-22 and IL-17F from immune cells as well as in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease, ulcerative colitis and multiple sclerosis.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: April 12, 2022
    Assignee: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
  • Patent number: RE49035
    Abstract: A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: April 19, 2022
    Assignee: Tasly Pharmaceutical Group Co., Ltd.
    Inventors: Xijun Yan, Naifeng Wu, Kaijing Yan, Zhengliang Ye, Shunnan Zhang, Lihong Zhou, Wensheng Zhang, Hai'ou Dong
  • Patent number: RE49037
    Abstract: The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 ?g/ml, compositions containing the same and uses thereof.
    Type: Grant
    Filed: December 24, 2019
    Date of Patent: April 19, 2022
    Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute, Cornell University
    Inventors: Dennis R. Burton, Marit J. Van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok
  • Patent number: RE49050
    Abstract: A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: April 26, 2022
    Assignee: Tasly Pharmaceutical Group Co., Ltd.
    Inventors: Xijun Yan, Naifeng Wu, Kaijing Yan, Zhengliang Ye, Shunnan Zhang, Lihong Zhou, Wensheng Zhang, Hai'ou Dong, Yongfeng Zheng, Lijun Fan
  • Patent number: RE49076
    Abstract: Compositions and methods are disclosed herein for treating or reducing the symptoms of a renal disease, such as focal segmental glomerulosclerosis (FSGS), hypertensive end-stage kidney disease (ESKD), and HIV-associated nephropathy (a distinct form of FSGS, also termed collapsing glomerulopathy). The compositions include the common variant of APOL1 and fragments thereof, as well as antibodies and fragments thereof that bind and neutralize pathogenic APOL1, nucleic acid molecules that encode the common variant of APOL1 and fragments thereof, and other compounds that bind and neutralize pathogenic APOL1. The methods of the invention include administering one or more of the compositions of the invention to a subject having or at risk of developing renal disease.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: May 17, 2022
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: David J. Friedman, Martin R. Pollak
  • Patent number: RE49121
    Abstract: A genetically modified mouse is provided that comprises a conditional Acvr1 allele that comprises a mutated exon that, upon induction, converts to a mutant exon phenotype, wherein the mutant exon phenotype includes ectopic bone formation. Mice comprising a mutant Acvr1 exon 5 in antisense orientation, flanked by site-specific recombinase recognition sites, are provided, wherein the mice further comprise a site-specific recombinase that recognizes the site-specific recombinase recognitions sites, wherein the recombinase is induced upon exposure of the mouse to tamoxifen. Upon exposure to tamoxifen, the recombinase is expressed and acts on the RRS-flanked mutant exon 5 and places the mutant exon 5 in sense orientation and deletes the wild-type exon.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: July 5, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aris N. Economides, Sarah Jane Hatsell
  • Patent number: RE49129
    Abstract: The present invention relates to methods of treatment of Hypoxia Inducible Factor (HIF)-related conditions, and in particular to methods of treatment of HIF-related conditions comprising the administration of a composition comprising transferrins.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: July 12, 2022
    Assignee: GRIFOLS WORLDWIDE OPERATIONS LIMITED
    Inventors: David A. Ross, Ralph Christian Crumrine
  • Patent number: RE49192
    Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: August 30, 2022
    Assignee: INTERNATIONAL—DRUG—DEVELOPMENT BIOTECH
    Inventors: Claudine Vermot-Desroches, Boris Sebastien Vuillermoz
  • Patent number: RE49207
    Abstract: Provided herein, among other things, are a variety of methods for transposase-mediated tagging and amplification of short DNA fragments, e.g., between about 150 bp and 1.5 Kb in length. In some aspects, the method includes tagging the DNA fragments with a first primer sequence using barcoded transposases followed by a primer extension reaction to introduce a second primer sequence, e.g., using random or gene-specific primers. Kits for performing this method are also provided.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: September 13, 2022
    Assignee: Agilent Technologies, Inc.
    Inventors: Bahram Arezi, Michael Borns, Holly Hogrefe, Connie Hansen
  • Patent number: RE49229
    Abstract: This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-?.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: October 4, 2022
    Assignee: NITTO DENKO CORPORATION
    Inventors: Kenjirou Minomi, Jihua Liu, Li Wang, Bharat Majeti, Roger Adami, Wenbin Ying
  • Patent number: RE49238
    Abstract: Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD).
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: October 11, 2022
    Assignee: Retrotope, Inc.
    Inventor: Mikhail S. Shchepinov
  • Patent number: RE49281
    Abstract: The invention provides compositions and methods of use in reprogramming somatic cells. Compositions and methods of the invention are of use, e.g., for generating or modulating (e.g., enhancing) generation of induced pluripotent stem cells by reprogramming somatic cells. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a pluripotent state and/or enhances the speed and/or efficiency of reprogramming. Certain of the compositions and methods relate to modulating the Wnt pathway.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: November 8, 2022
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Brett Chevalier, Alexander Marson, Richard A. Young, Ruth Foreman, Rudolf Jaenisch
  • Patent number: RE49293
    Abstract: Gas permeable devices and methods are disclosed for cell culture, including cell culture devices and methods that contain medium at heights, and certain gas permeable surface area to medium volume ratios. These devices and methods allow improvements in cell culture efficiency and scale up efficiency.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: November 15, 2022
    Assignee: Wilson Wolf Manufacturing
    Inventors: John R. Wilson, Douglas A. Page, Daniel Welch, Alison Robeck
  • Patent number: RE49294
    Abstract: A vector production system is provided. The system comprises recombinant cells designed to encode at least a first recombinase under the control of an inducible promoter and the cells include an expression vector encoding a nucleic acid of interest within the regulatory elements of the expression vector which are flanked on either side by a target sequence for at least the first recombinase. The vector production system provides an efficient one-step process for producing linear or circular covalently closed vectors that incorporate a nucleic acid sequence of interest.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: November 15, 2022
    Assignee: Mediphage Bioceuticals, Inc.
    Inventors: Roderick Slavcev, Nafiseh Nafissi
  • Patent number: RE49304
    Abstract: Provided herein are compositions and methods for identifying or quantitating one or more analytes in sample. The composition can comprise an affinity molecule reversibly conjugated to a label moiety via a double-stranded nucleic acid linker or via an adaptor molecule. The affinity molecule and the label moiety can be linked to different strands of the double-stranded nucleic acid linker. Compositions can be used in any biological assays for detection, identification and/or quantification of target molecules or analytes, including multiplex staining for molecular profiling of individual cells or cellular populations. For example, the compositions can be adapted for use in immunofluorescence, fluorescence in situ hybridization, immunohistochemistry, western blot, and the like.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: November 22, 2022
    Assignee: University of Washington
    Inventors: Xiaohu Gao, Pavel Zrazhevskiy